Details for Patent: 5,464,826

Summary for Patent: 5,464,826

Title:	Method of treating tumors in mammals with 2',2'-difluoronucleosides
Abstract:	A method of treating susceptible neoplasms in mammals comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound of the formula ##STR1## wherein: R.sup.1 is hydrogen; R.sup.2 is a base defined by one of the formulae ##STR2## X is C-R.sup.4 ; R.sup.3 is hydrogen; R.sup.4 is hydrogen, C.sub.1 -C.sub.4 alkyl, bromo, fluoro, chloro or iodo; and the pharmaceutically-acceptable salts thereof.
Inventor(s):	Grindey; Gerald B. (Indianapolis, IN), Hertel; Larry W. (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	08/280,687
Patent Claim Types: see list of patent claims	Use; Compound;

United States Patent 5,464,826: A Detailed Analysis

Introduction

The United States Patent 5,464,826, titled "Method of treating tumors in mammals with 2',2'-difluoronucleosides," is a significant invention in the field of oncology. This patent describes a method for treating tumors in mammals using 2',2'-difluoronucleosides, which are compounds that have shown potential in inhibiting cancer cell growth[1].

Scope of the Patent

The patent's scope encompasses the use of 2',2'-difluoronucleosides for treating susceptible neoplasms in mammals. The invention includes the synthesis and formulation of these compounds, as well as their application in pharmaceutical preparations[1].

Claims

The patent claims include:

• Compound Formulation: The patent describes the synthesis of specific compounds, such as 1-(4-amino-5-iodo-2-oxo-1H-pyrimidin-1-yl)-2-desoxy-2,2-difluororibose, and their pharmaceutically acceptable salts[1].
• Pharmaceutical Formulations: The invention provides pharmaceutical formulations useful for treating susceptible neoplasms in mammals, comprising a compound of formula I with a suitable pharmaceutically acceptable carrier, diluent, or excipient[1].
• Method of Treatment: The patent claims a method of treating tumors in mammals using the synthesized compounds, which involves administering these compounds to the affected area to inhibit tumor growth[1].

Patent Landscape Analysis

To understand the patent landscape, we must consider the broader context of intellectual property in the chemical industry.

Patent Search Strategy

A patent search strategy for identifying relevant documents would involve collecting data from the United States Patent and Trademark Office (USPTO), the World Intellectual Property Organization (WIPO), and the European Patent Office (EPO) databases. This includes conducting preliminary searches of patents and technical literature, collaborating with technical teams and market experts, and establishing a collection of relevant keywords, patent class codes, and organizations operating in the technical field[3].

Categorization of Patents

The collected data would be categorized based on title, abstract, claims, and full specifications. This step involves manual reading to classify the results into more accurate and relevant categories. The categorization results in a valuable hierarchy that can be used by IP experts for extracting insights such as identifying gaps, key inventors, filing year trends, and top filing countries[3].

Legal Status and Expected Expiry Dates

Understanding the legal status and expected expiry dates of patents is crucial. The patent landscape report would include details like alive, pending, lapsed, revoked, and expired status of patents. Including expected expiry dates aids in decision-making and helps in evaluating technology impact on the market[4].

Double Patenting Considerations

The patent landscape also involves considerations related to double patenting. Double patenting refers to the prohibition against obtaining two patents for the same invention. The asserted claims of the later '826 patent simply claim the anticancer use disclosed in the specification of the '614 patent. This highlights the importance of narrowly tailoring claims to what is actually conceived by the named inventors to avoid invalidation due to obviousness-type double patenting[5].

Key Takeaways

1. Invention Scope: The patent covers the synthesis and application of 2',2'-difluoronucleosides for treating tumors in mammals.
2. Claims Specificity: The claims include specific compound formulations and pharmaceutical preparations.
3. Patent Landscape Analysis: Understanding the broader patent landscape involves collecting and categorizing data from various IP offices.
4. Double Patenting Considerations: The patent must avoid obviousness-type double patenting by ensuring that the claims are specific and not overly broad.

FAQs

1. What is the primary focus of United States Patent 5,464,826?

   • The primary focus is on the method of treating tumors in mammals using 2',2'-difluoronucleosides.

2. How are the compounds synthesized?

   • The compounds are synthesized by reacting a D-glyceraldehyde ketonide with a C1-C4 alkyl bromodifluoroacetate to afford an alkyl 3-dioxolanyl-2,2-difluoro-3-hydroxypropionate[1].

3. What is the significance of the patent landscape analysis?

   • The patent landscape analysis helps in understanding the entire landscape of a technology domain and offers valuable insights into competitors, including identifying gaps, key inventors, filing year trends, and top filing countries[3].

4. How does double patenting affect this patent?

   • Double patenting considerations are crucial as the patent must avoid obviousness-type double patenting by ensuring that the claims are specific and not overly broad[5].

5. What are the implications for pharmaceutical companies?

   • The implications are significant as pharmaceutical companies need to ensure that their claims are narrowly tailored to avoid invalidation due to double patenting, while also leveraging the insights from patent landscape analysis to capitalize on market opportunities[3].

Conclusion

United States Patent 5,464,826 is a critical invention in oncology, providing a method for treating tumors using 2',2'-difluoronucleosides. Understanding the scope and claims of this patent, along with the broader patent landscape and double patenting considerations, is essential for pharmaceutical companies aiming to dominate the market with innovative treatments.

Sources Cited

1. [US5464826A - Method of treating tumors in mammals with 2',2'-difluoronucleosides - Google Patents][1]
2. [Intellectual Property Technology Law Journal - Akin Gump][2]
3. [Navigating Technological Domains with Patent Landscape Analysis - Sagacious Research][3]
4. [Search for patents - USPTO][4]
5. [Double Patenting - AIPLA][5]

Drugs Protected by US Patent 5,464,826

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 5,464,826

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	92499
Australia	5055585
Australia	581269